Inari Medical Presents PEERLESS Trial Findings
Inari Medical, Inc. (NASDAQ: NARI), an innovative medical device company focused on improving the lives of patients with venous and other diseases, has announced the upcoming presentation of data from the important PEERLESS trial. Dr. Wissam Jaber, a Professor of Medicine, will present these findings during the Late-Breaking Clinical Trial Sessions at the prestigious Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium.
Details of the PEERLESS Trial
The PEERLESS trial is a carefully structured prospective, randomized controlled trial (RCT) that assesses the effectiveness of the FlowTriever system compared to catheter-directed thrombolysis in treating patients with intermediate-risk pulmonary embolism (PE). The primary goal of this trial is to conduct a thorough win-ratio analysis that examines key clinical outcomes and the use of hospital resources.
Importance of the Research
This pioneering study seeks to provide healthcare professionals with crucial insights into the best treatment strategies for patients facing pulmonary embolism. By aiming to generate high-quality clinical evidence, the PEERLESS trial holds significant importance and highlights Inari's dedication to enhancing medical knowledge in the area of venous thromboembolism (VTE).
Insights from Experts on the PEERLESS Trial
Dr. Thomas Tu, Inari’s Chief Medical Officer, stressed the significance of this trial, stating, “PEERLESS is the first RCT that directly compares the FlowTriever to a historical treatment option for PE. It also marks the start of several RCTs that Inari is pursuing within the VTE field.” His comments reflect the company’s eagerness to provide essential evidence that patients and healthcare providers can trust when making vital treatment choices.
Dedication to Enhancing Patient Outcomes
Inari Medical is deeply committed to improving patient lives through innovative solutions designed to meet critical healthcare needs. The company’s core principles—prioritizing patients, aiming for ambitious goals, and nurturing a supportive environment—continue to drive their mission. As they roll out their purpose-built solutions, Inari also emphasizes the importance of educating healthcare providers and advancing clinical research initiatives to promote better patient outcomes.
About Inari Medical, Inc.
Inari Medical leads the way in innovation within the medical device industry by focusing on the healthcare needs of patients dealing with venous thromboembolism and other chronic conditions. Their mission combines innovative product development with educational efforts aimed at supporting clinical practices that uphold the highest standards of care. As they grow their product portfolio, they are committed to establishing their treatments as the gold standard for addressing various venous-related health challenges.
Contact Information
For additional inquiries, please contact:
Investor Contact:
Marissa Bych
Gilmartin Group LLC
Email: IR@inarimedical.com
Frequently Asked Questions
What is the PEERLESS trial about?
The PEERLESS trial is a randomized controlled trial that compares the FlowTriever system with catheter-directed thrombolysis in treating patients with intermediate-risk pulmonary embolism.
Who presented the data from the PEERLESS trial?
Dr. Wissam Jaber, a Professor of Medicine, presented the data during the Late-Breaking Clinical Trial Sessions at the TCT symposium.
What is the primary endpoint of the PEERLESS trial?
The main endpoint includes a win-ratio analysis focused on critical clinical and hospital resource utilization outcomes.
What does Inari Medical aim to achieve with this trial?
Inari Medical aims to provide high-quality clinical evidence that will inform treatment decisions for patients suffering from pulmonary embolism.
How can I learn more about Inari Medical?
More information about Inari Medical and their initiatives can be found on their official website and social media platforms, including LinkedIn and Twitter.
